ALARICE: Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy

The University of Hong Kong (Other)
Overall Status
Recruiting ID

Study Details

Study Description

Brief Summary

This is a single-arm, Simon's 2-stage, proof-of-concept trial. The aim is to evaluate the efficacy and safety of avelumab with axitinib in patients with persistent or recurrent cervical cancer following platinum-based chemotherapy. The study hypothesis is that the combination of avelumab and axitinib can significantly improve the objective response rate (ORR) with acceptable toxicity compared to traditional chemotherapy.

Condition or Disease Intervention/Treatment Phase

Detailed Description

Cervical cancer is the fourth commonest female cancer in the world. When there is distant metastasis or recurrence, platinum-based chemotherapy is the usual treatment option. Once this first-line chemotherapy fails, the prognosis is dismal. Various second-line agents including second-line chemotherapy agents and immune checkpoint inhibitors have unsatisfactory response rate.

Study Design

Study Type:
Anticipated Enrollment :
23 participants
Intervention Model:
Single Group Assignment
None (Open Label)
Primary Purpose:
Official Title:
Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy - a Proof-of-concept Study (ALARICE Study)
Actual Study Start Date :
Jun 1, 2019
Anticipated Primary Completion Date :
Mar 1, 2024
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Avelumab and Axitinib

Avelumab: IV treatment; administered at 10 mg/kg IV every two weeks in a 4-weekly cycle up to 12 cycles or until disease progression or intolerable side effects (whichever occurs first) Axitinib: Oral treatment; administered at 5 mg PO BID in a 4-weekly cycle up to 12 cycles or until disease progression or intolerable side effects (whichever occurs first)

Drug: Avelumab
an anti-programmed cell death ligand 1
Other Names:
  • Bavencio
  • Drug: Axitinib
    a tyrosine kinase inhibitor that also inhibits VEGF receptor 1-3, c-KIT and PDGFR
    Other Names:
  • Inlyta
  • Outcome Measures

    Primary Outcome Measures

    1. Objective response rate (ORR) [Up to 2 years]

      ORR is defined as the proportion of patients who have a CR or PR to the study drugs.

    Secondary Outcome Measures

    1. Progression-free survival (PFS) [Up to 2 years]

      The time from first dose of trial medication to first documentation of objective tumor progression (PD) or to death due to any cause, whichever occurs first.

    2. Overall survival [Up to 2 years]

      Overall survival is defined as the time from first dose of trial medication to date of death due to any cause.

    3. Objective tumor response rate [Up to 2 years]

      Objective tumor response rate according to the immune-related ResponseCriteria Derived from RECIST 1.1 (irRECIST)

    4. Disease control rate at 12 weeks [Up to 2 years]

      Disease control rate at 12 weeks including complete response (CR), partial response (PR), stable disease (SD)

    5. Duration of response [Up to 2 years]

      Duration of response and duration of clinical benefit including CR, PR and SD

    6. Rates of abnormal laboratory values and/or adverse events that are related to the treatment drugs [Up to 2 years]

      Treatment-related adverse events classified by CTCAE version 5.0 and laboratory safety assessments

    Eligibility Criteria


    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Accepts Healthy Volunteers:
    Inclusion Criteria:
    1. Patients must be at least 18 years old.

    2. Patients must have histologically confirmed cervical cancer, either squamous cell, adenocarcinoma or adenosquamous, that is either persistent or recurrent after at least one prior course of platinum-based chemotherapy. The platinum used in concurrent chemo-irradiation is not counted.

    3. Patients should not be amenable to further surgery or radiotherapy except for the purpose of symptomatic relief.

    4. Patients should have ECOG performance score 0 to 2.

    5. Patients must have at least one target lesion by the RECIST 1.1 criteria.

    6. Prior chemotherapy must have been completed at least 3 weeks before study drug administration, and all AEs have either returned to baseline or stabilized.

    7. Prior systemic radiation therapy must have been completed at least 4 weeks before study drug administration. Prior focal radiotherapy must have completed at least 2 weeks before study drug administration.

    8. Patients must have recovered from any major surgery that has been done at least 4 weeks before study drug administration.

    9. Patients must have adequate bone marrow, renal, hepatic, thyroid and neurological function.

    10. Patients should be willing to have blood tests where the blood will be used for biomarker studies.

    11. Formalin-fixed, paraffin-embedded (FFPE) archival tumor specimens of the primary tumors, should be available during screening. Alternatively, 15 unstained slides (6 minimum) will be acceptable.

    12. Patients should agree for de novo biopsy if the tumors are at the cervix or vagina, or any other sites that are easy and safe to be biopsied. Tumors will be used for biomarker studies.

    13. Patients who have childbearing potential should practice highly effective contraception throughout the study until at least 30 days after completion of the treatment

    Exclusion Criteria:
    1. Patients with concurrent malignancy within five years (except for basal or squamous cell skin cancer or in-situ breast cancer) are excluded.

    2. Patients who have history of autoimmune diseases or other diseases requiring systemic steroid are excluded.

    Patients with vitiligo, type I diabetes mellitus, resolved asthma or atopy, stable autoimmune thyroid disease, eczema, psoriasis not requiring systemic treatment*, or not expected to recur in the absence of an external trigger are permitted to enroll.

    1. Patients with the following past significant medical history in the last six months are excluded, such as pneumonitis, active or chronic viral hepatitis, cirrhosis, and inherited liver disease, myocardial infarction, unstable angina, unstable cardiac arrhythmia or clinically significant valvular heart diseases, CTCAE Grade 2 or greater peripheral vascular disease, active brain metastases or leptomeningeal metastases, uncontrolled seizures, subarachnoid hemorrhage, thromboembolic events.

    2. Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone or equivalents) or other immunosuppressive medications within 14 days of the start of treatment are excluded. Inhaled, local or topical steroids, systemic corticosteroids at physiologic doses, steroid used as pre-medication are allowed.

    3. Patients with severe gastrointestinal conditions such as evidence of bowel obstruction or uncontrolled diarrhea in the last 4 weeks prior to enrollment, or history of inflammatory bowel disease, are not eligible.

    4. Patients with uncontrolled hypertension (systolic >160mmHg or diastolic > 110mmHg) despite medication, active bleeding, bone fracture, unhealed wounds, clinically significant proteinuria (> 2g of protein over 24 hours), are excluded.

    5. Patients with unhealed wounds include abdominal or pelvic fistula, gastrointestinal perforation or intra-abdominal abscess are excluded.

    6. Patients having had severe infections within 4 weeks prior to the start of treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, and those who have active infection requiring systematic treatment, are excluded.

    7. Patents with active tuberculosis, history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) are excluded.

    8. Patients who have suicidal ideations or behaviors requiring psychiatric intervention within 3 months prior to the start of treatment are excluded.

    9. Patients who have history of severe (CTCAE Grade 3 or above) hypersensitivity reaction to any investigational products or any component in its formulations, and any monoclonal antibody, are excluded.

    10. Patients who have known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the avelumab formulation.

    11. Patients who have persisting toxicities related to previous therapy (NCI CTCAE v 5.0 Grade >1) are excluded. However, alopecia, Grade 2 or less sensory neuropathy, or other toxicities of Grade 2 or below that do not constitute a safety risk according to the investigators' judgment, are allowed.

    12. Patients who have received prior immunotherapy, such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways, are excluded.

    13. Patients who have received axitinib before are excluded.

    14. Patients who received other anti-angiogenics within the last 6 months are excluded.

    15. Patients with prior allogeneic stem cell or solid organ transplantation are excluded.

    16. Use of other investigational drugs (drugs not marketed for any indication) within 28 days or at least 5 half-lives (whichever is longer) before the start of treatment, or during the course of this trial, is not allowed.

    17. Use of any live attenuated vaccines against infectious diseases (e.g. influenza, varicella, etc.) within 4 weeks (28 days) of the start of treatment and during the study therapy is not allowed.

    18. Patients with major operation within 28 days or open biopsy within 7 days before enrolment are not eligible.

    19. Patients planned to have major surgery during the course of the study are excluded.

    20. Patients who are pregnant or breastfeeding are excluded.

    Contacts and Locations


    Site City State Country Postal Code
    1 The University of Hong Kong Hong Kong Hong Kong

    Sponsors and Collaborators

    • The University of Hong Kong


    • Principal Investigator: Ka Yu Tse, The University of Hong Kong

    Study Documents (Full-Text)

    None provided.

    More Information


    None provided.
    Responsible Party:
    Dr. Ka-Yu Tse, Clinical Associate Professor, The University of Hong Kong Identifier:
    Other Study ID Numbers:
    • WI224183 / UW 18-417
    First Posted:
    Feb 1, 2019
    Last Update Posted:
    Feb 24, 2022
    Last Verified:
    Feb 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Plan to Share IPD:
    Studies a U.S. FDA-regulated Drug Product:
    Studies a U.S. FDA-regulated Device Product:
    Product Manufactured in and Exported from the U.S.:
    Keywords provided by Dr. Ka-Yu Tse, Clinical Associate Professor, The University of Hong Kong
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 24, 2022